SHH and cancer: Based on the high anti-cancer activity of the SHH pathway-inhibitor ACVR1 in preclinical studies, a variety of clinically active small molecule inhibitors were developed including saridegib, erismodegib, or vismodegib [249], the latter showing promising clinical responses in SHH-driven MB [303].